The writers of this article conducted an experiment that experiment with new therapies that target pathway of PAH to treat ES, which has been shown to be more effective in comparison to other treatments. Multiple therapies such as, phosphodiesterase type 5 inhibitor, endothelin receptor antagonist Bosentan, and prostacyclin analogs are tested and compared to one another in this piece. The experiments have led to the conclusion that the combination of these therapies offer one of the best alternative choices for people who have been diagnosed with ES
Methods:
The methods that was used in this experiment was testing different therapy and drugs for patient with Eisenmenger Syndrome. Endothelin receptor antagonist Bosentan method was …show more content…
The 6 month therapy showed an improved in exercise capacity, this therapy also can cause side effects to the patient. The last Prostacyclin therapy was observed, the 8 patient treatment showed that it can enhance exercise capacity and oxygen saturation, and decrease PVR.
Finding:
These Therapies endothelin receptor antagonists, prostacyclin, phosphodiesterase type-5 inhibitors can enhance exercise capacity, and oxygen saturation by using treatments methods. The authors of this study stated that these treatment a new and should be continued in studies for patient with ES.
Critique:
These experiments can be used to understand the new therapies and how they can be improved to become more effective or be more beneficial with treatment this disorder. Although the these therapies may help patients with exercise capacity, they also have a can effect a patient with different side effects, like Bosentan which can effect a patient liver if it continue to be used. The other therapies also have som effect to a person health. The therapies should be further studied and investigated, also learn new drugs that may less harmful to the